Biologically Active Substance – Page 12

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

6 months ago6 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

6 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

PTC crashes as win for Novartis-partnered Huntington’s drug fails to convince investors

6 months ago talkbio0Tagged Accelerated, Approved, factor IX, PTC518, United States Food and Drug Administration

factor IX, PTC518, Accelerated, Approved, United States Food and Drug Administration

PTC’s Novartis-partnered Huntington’s drug disappoints in mid-stage data reveal

6 months ago talkbio0Tagged factor IX, Huntington 's disease, Market, PTC518

PTC518, factor IX, Huntington ‘s disease, Market

FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme

6 months ago talkbio0Tagged Atara, Atara 's, Ebvallo, Hoist device, Study on Hold, United States Food and Drug Administration

United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO

Novo eyes fourth-quarter FDA verdict for oral Wegovy filing

6 months ago talkbio0Tagged Decision, Novo, Obesity, Oral cavity, Overweight, semaglutide, United States Food and Drug Administration, Wegovy

Obesity, Novo, United States Food and Drug Administration, Decision, Oral cavity, Wegovy, semaglutide, Overweight

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

6 months ago talkbio0Tagged Dependovirus, gene therapy, Industry, Partnership, research, Safety, Transfer RNA

gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

6 months ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival